As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study
Joshua A Gordon
5-MeO-DMT, a natural tryptamine, shows psychedelic effects by acting on serotonin receptors. Clinical trials suggest its potential for rapidly reducing depression symptoms, prompting further studies for depression treatment.
Johannes Reckweg
Manoj Doss discusses psychedelic impact on episodic memories, highlighting FLUX theory. Fred Barrett explores psychedelic therapy's potential for lasting shifts in psychological and cognitive flexibility across disorders.
Frederick Barrett, Manoj K. Doss
Imran Khan presents findings of the Psychedelic Insight Poll, a national survey by the Berkeley Center for the Science of Psychedelics to understand public perceptions of psychedelic substances. The poll
Imran Khan
Psychedelic drugs may enhance creative thinking and empathy, supported by anecdotal reports and some scientific evidence. Studies show time- and construct-dependent effects on flexible cognition, with brain imaging linking changes
Natasha Mason
Drs. Summergrad and Insel reflect on the progress and remaining questions in psychedelic science since 2017. They delve into topics like efficacy, regulation, therapy, and provider experience.
Paul Summergrad, Tom Insel, Rachel Nuwer
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Clinical trials show potential of psychedelics for psychiatric treatment, but studies note varied responses. Unclear clinical mechanism discussed in talk on neurobiology and optimizing psychedelic therapy.
Dr. Dölen presents evidence linking psychedelics to reopening the social reward learning critical period, suggesting a shared mechanism across these drugs. This metaplastic restoration of oxytocin-mediated long-term depression may have
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.